Disc Medicine is cutting 30 people, about 20% of its workforce, after receiving an FDA rebuff on its lead program. The cuts target commercial roles that were built in anticipation of a product launch that is now delayed or uncertain.
This is a textbook biotech contraction: a company staffs up for commercialization, the regulatory pathway hits a roadblock, and the commercial team is no longer needed. The 30 affected employees are collateral damage of the binary nature of drug development, where a single FDA decision can reshape an entire company overnight.